+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hot Flashes Associated with Prostate Cancer Treatment - Market Insights, Epidemiology, and Market Forecast - 2028

  • ID: 4911962
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 154 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

The ‘Hot Flashes Associated with Prostate Cancer Treatment - Market Insights, Epidemiology, and Market Forecast - 2028’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Hot Flashes Associated with Prostate Cancer Treatment in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Hot Flashes Associated with Prostate Cancer Treatment from 2017 to 2028 segmented by seven major markets.

Cancer starts when cells in the body activate and grow out of control. In any part of the body, cells can become cancer cells and then can spread to other parts and areas of the body. Prostate cancer arises when cells in the prostate gland start to grow out of control. The prostate is a gland found only in males. It makes some of the fluid which is a part of the semen. For the treatment of prostate cancer ADT is the preferred medication which causes hot flashes which is the major side effect of the treatment.

The hot flash vasomotor phenomena are symptoms that usually result from biochemical disturbances of normal functioning. They might also result in a significance of bilateral orchiectomy, oophorectomy, or pharmacologic therapies. Although these symptoms are not considered life-threatening, hot flashes significantly impact the quality of life (QOL).

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017–2028.

Hot Flashes Associated with Prostate Cancer Treatment - Disease Understanding and Treatment Algorithm

Hot flashes are described as spontaneous and transient sensations of warmth, varying in severity, which is usually followed by perspiration. Flashing, sweating, palpitations, sleep disturbances, skin blotching, and anxiety are among other symptoms that can accompany hot flashes. The symptoms of hot flashes are a concern of vasomotor variability because of thermoregulatory dysfunction within the hypothalamus and the influence that the hypothalamus has on peripheral vasodilatory mechanisms. Three key neurotransmitters that have been identified in the stimulation of hot flash physiology: endorphins, catechol estrogens, and serotonin. Estrogen and testosterone increase the production of α-endorphins; as sex hormone concentrations decrease, hypothalamic norepinephrine concentrations increase. But the accurate characterization of the severity and frequency of hot flashes can be difficult because they are independent sensations.

Four categories have been used to describe hot flash severity for men. These categories include mild, moderate, severe, and very severe. A mild hot flash is defined as a generalized warmth or a flushed sensation lasting < 3 min. A moderate hot flash lasts < 5 min and is connected with more warmth and/or flushing than a mild hot flash. Severe hot flashes last < 10 min and are described by patients as hot or very hot and are escorted by moderate anxiety or irritability, heavy sweat, and extreme distress, often demanding a change of clothing or bedding. A very severe hot flash is defined as a very hot sensation enduring < 30 min and drenching sweat demanding a change of clothing or bedding and a bath or shower.

Hot Flashes Associated with Prostate Cancer Treatment Epidemiology

The Hot Flashes Associated with Prostate Cancer Treatment epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the incident pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent Patient Population of Hot Flashes Associated with Prostate Cancer, Prostate Cancer by Stages, Progression from local and regional to advance cases, Hormone-sensitivity cases of Prostate cancer in Advance Stage, ADT use cases in Prostate Cancer, Rate of Hot Flashes Associated with Prostate Cancer, Hot Flashes cases by Severity) scenario of Hot Flashes Associated with Prostate Cancer Treatment in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.

According to this research, the total Diagnosed Prevalent Patient Population of Hot Flashes Associated with Prostate Cancer in the 7MM was found to be 1,024,536 in 2017. The total Diagnosed Prevalent Patient Population of Hot Flashes Associated with Prostate Cancer in the 7MM is expected to increase during the study period of 2017–2028.

Among 7MM, the United States has the highest total Diagnosed Prevalent Patient Population of Hot Flashes Associated with Prostate Cancer about 430,473 cases in 2017. Among EU5 countries, Germany had the highest number of total Diagnosed Prevalent Patient Population of Hot Flashes Associated with Prostate Cancer with approximately 128,954 cases, followed by France with approximately 126,272 cases in 2017. In Spain, mild, moderate and severe cases for hot flashes were 19,864, 21,519, and 17,735 cases in 2017. In Italy, 83,479 and 24,596 cases were observed using ADT in Hormone-sensitive and ADT use in hormone resistant prostate cancer in 2017.

Hot Flashes Associated with Prostate Cancer Treatment Drug Chapters

This segment of the Hot Flashes Associated with Prostate Cancer Treatment report encloses the detailed analysis of pipeline drug. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, the therapeutic market size of Hot Flashes Associated with Prostate Cancer in the US is mainly accounted for the management options consisting of pharmacologic treatment options and non-pharmacological therapies.

Pharmacologic treatment options include hormonal therapies (estrogen, Megestrol acetate, Medroxyprogesterone acetate, and cyproterone acetate) and nonhormonal therapies (Clonidine, Venlafaxine, Fluoxetine, Paroxetine, and Gabapentin). Non-pharmacological therapies include vitamin E, soy products, black cohosh acupuncture, and herbal remedies.

Detailed chapters of current therapies and emerging therapies, such as Zuclomiphene Citrate (Veru-944) by Veru Pharma have also been provided in the report.

Hot Flashes Associated with Prostate Cancer Treatment Market Outlook

The Hot Flashes Associated with Prostate Cancer Treatment market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

According to this research, the market for Hot Flashes Associated with Prostate Cancer Treatment in 7MM was found to be approximately USD 162.64 Million in 2017.

Hot Flashes Associated with Prostate Cancer Treatment market size in the United States accounted for 45% of the total market in 2017. The US led the market in 2017, followed by the EU5 and Japan, respectively. Due to the increasing cases of this disease in the region, the Hot Flashes Associated with Prostate Cancer Treatment treatment market in the US is expected to dominate the market during the forecast period (2019–2028).

Hot Flashes Associated with Prostate Cancer Treatment Drugs Uptake

This section focuses on the rate of uptake of the potential drugs that will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by the drug; patient uptake by therapies, and sales of each drug.

The dynamics of Hot Flashes Associated with Prostate Cancer Treatment market is anticipated to change in the coming years owing to the expected launch of emerging therapy, such as Zuclomiphene Citrate (Veru-944) by Veru Pharma and others in the Hot Flashes Associated with Prostate Cancer Treatment market by 2028.

Hot Flashes Associated with Prostate Cancer Treatment Report Insights
  • Patient Population of Hot Flashes Associated with Prostate Cancer Treatment
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Hot Flashes Associated with Prostate Cancer Treatment Report Key Strengths
  • 10-Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Hot Flashes Associated with Prostate Cancer Treatment Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Hot Flashes Associated with Prostate Cancer Treatment market
  • Organize sales and marketing efforts by identifying the best opportunities for Hot Flashes Associated with Prostate Cancer Treatment market
  • To understand the future market competition in the Hot Flashes Associated with Prostate Cancer Treatment market
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

1. Key Insights

2. Region-Wise Market Share (%) Distribution of Hot Flashes Associated with Prostate Cancer Treatment in 2017

3. Region-Wise Market Share (%) Distribution of Hot Flashes Associated with Prostate Cancer Treatment in 2028

4. Disease Background and Overview: Hot Flashes Associated with Prostate Cancer Treatment
4.1. Introduction
4.2. Risk Factors for Prostate Cancer
4.3. Symptoms
4.4. Stages and Grades
4.5. Pathophysiology
4.6. Histopathology
4.7. Diagnosis

5. Androgen Deprived Therapy (ADT)-Associated Prostate Cancer Treatment
5.1. Treatment to lower testicular androgen levels
5.1.1. Orchiectomy
5.1.2. Luteinizing hormone-releasing hormone (LHRH) agonists
5.1.3. Luteinizing hormone-releasing hormone (LHRH) antagonists
5.2. Treatment to lower androgen levels from the adrenal glands
5.3. Drugs that stop androgens from working
5.3.1. Anti-androgens
5.3.2. Newer anti-androgens

6. Recognized Establishments

7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Cases of Hot Flashes Associated with Prostate Cancer Treatment in the 7MM

8. Country Wise-Epidemiology of Hot Flashes Associated with Prostate Cancer Treatment
8.1. United States
8.1.1. Assumptions and Rationale
8.1.2. Mortality adjusted Diagnosed Prevalent Population of Prostate Cancer in the United States
8.1.3. Prostate Cancer by Stages in the United States
8.1.4. Progression from local and regional to advance stage in the United States
8.1.5. Hormone-sensitivity of Prostate cancer in Advance Stage in the United States
8.1.6. ADT use in Prostate Cancer in the United States
8.1.7. Rate of Hot Flashes Associated with Prostate Cancer Treatment in the United States
8.1.8. Hot Flashes by Severity in the United States
8.2. EU5 Countries
8.2.1. Assumptions and Rationale
8.3. Germany
8.3.1. Mortality adjusted Diagnosed Prevalent Population of Prostate Cancer in Germany
8.3.2. Prostate Cancer by Stages in Germany
8.3.3. Progression from local and regional to advance stage in Germany
8.3.4. Hormone-sensitivity of Prostate cancer in Advance Stage in Germany
8.3.5. ADT use in Prostate Cancer in Germany
8.3.6. Rate of Hot Flashes Associated with Prostate Cancer Treatment in Germany
8.3.7. Hot Flashes by Severity in Germany
8.4. France
8.4.1. Mortality adjusted Diagnosed Prevalent Population of Prostate Cancer in France
8.4.2. Prostate Cancer by Stages in France
8.4.3. Progression from local and regional to advance stage in France
8.4.4. Hormone-sensitivity of Prostate cancer in Advance Stage in France
8.4.5. ADT use in Prostate Cancer in France
8.4.6. Rate of Hot Flashes Associated with Prostate Cancer Treatment in France
8.4.7. Hot Flashes by Severity in France
8.5. Italy
8.5.1. Mortality adjusted Diagnosed Prevalent Population of Prostate Cancer in Italy
8.5.2. Prostate Cancer by Stages in Italy
8.5.3. Progression from local and regional to advance stage in Italy
8.5.4. Hormone-sensitivity of Prostate cancer in Advance Stage in Italy
8.5.5. ADT use in Prostate Cancer in Italy
8.5.6. Rate of Hot Flashes Associated with Prostate Cancer Treatment in Italy
8.5.7. Hot Flashes by Severity in Italy
8.6. Spain
8.6.1. Mortality adjusted Diagnosed Prevalent Population of Prostate Cancer in Spain
8.6.2. Prostate Cancer by Stages in Spain
8.6.3. Progression from local and regional to advance stage in Spain
8.6.4. Hormone-sensitivity of Prostate cancer in Advance Stage in Spain
8.6.5. ADT use in Prostate Cancer in Spain
8.6.6. Rate of Hot Flashes Associated with Prostate Cancer Treatment in Spain
8.6.7. Hot Flashes by Severity in Spain
8.7. United Kingdom
8.7.1. Mortality adjusted Diagnosed Prevalent Population of Prostate Cancer in the United Kingdom
8.7.2. Prostate Cancer by Stages in the United Kingdom
8.7.3. Progression from local and regional to advance stage in the United Kingdom
8.7.4. Hormone-sensitivity of Prostate cancer in Advance Stage in the United Kingdom
8.7.5. ADT use in Prostate Cancer in the United Kingdom
8.7.6. Rate of Hot Flashes Associated with Prostate Cancer Treatment in the United Kingdom
8.7.7. Hot Flashes by Severity in the United Kingdom
8.8. Japan
8.8.1. Assumptions and Rationale
8.8.2. Mortality adjusted Diagnosed Prevalent Population of Prostate Cancer in Japan
8.8.3. Prostate Cancer by Stages in Japan
8.8.4. Progression from local and regional to advance stage in Japan
8.8.5. Hormone-sensitivity of Prostate cancer in Advance Stage in Japan
8.8.6. ADT use in Prostate Cancer in Japan
8.8.7. Rate of Hot Flashes Associated with Prostate Cancer Treatment in Japan
8.8.8. Hot Flashes by Severity in Japan
8.8.9. Rate of Hot Flashes Associated with Prostate Cancer Treatment in Japan
8.8.10. Hot Flashes by Severity in Japan

9. Treatment of Hot Flashes in Men
9.1. Pharmacologic Treatment
9.1.1. Hormonal therapies
9.2. Nonhormonal therapies
9.3. Nonpharmacologic Therapies

10. Unmet Needs

11. Emerging Drug
11.1. Zuclomiphene citrate (Veru-944): Veru Pharma
11.1.1. Product Description
11.1.2. Other Developmental Activities
11.1.3. Clinical Development
11.1.4. Product Profile

12. What Experts Say?

13. Hot Flashes Associated with Prostate Cancer Treatment: 7 Major Market Analysis
13.1. Key Findings
13.2. Hot Flashes Associated with Prostate Cancer Treatment Market Overview at a Glance
13.2.1. Market Share (%) Distribution of Hot Flashes Associated with Prostate Cancer Treatment in 2017
13.2.2. Market Share (%) Distribution of Hot Flashes Associated with Prostate Cancer Treatment in 2028
13.3. Market Size of Hot Flashes Associated with Prostate Cancer Treatment in the 7MM Countries

14. The United States Market Outlook
14.1. United States
14.1.1. Total Market size of Hot Flashes Associated with Prostate Cancer Treatment
14.1.2. Market Size by Therapies

15. EU-5 Countries: Market Outlook
15.1. Germany
15.1.1. Total Market size of Hot Flashes Associated with Prostate Cancer Treatment
15.1.2. Market Size by Therapies

16. France
16.1.1. Total Market size of Hot Flashes Associated with Prostate Cancer Treatment
16.1.2. Market Size by Therapies

17. Italy
17.1.1. Total Market Size of Hot Flashes Associated with Prostate Cancer Treatment
17.1.2. Market Size by Therapies

18. Spain
18.1.1. Total Market Size of Hot Flashes Associated with Prostate Cancer Treatment
18.1.2. Market Size by Therapies

19. United Kingdom
19.1.1. Total Market Size of Hot Flashes Associated with Prostate Cancer Treatment
19.1.2. Market Size by Therapies

20. Japan: Market Outlook
20.1. Japan market Size
20.1.1. Total Market Size of Hot Flashes Associated with Prostate Cancer Treatment
20.1.2. Market Size by Therapies

21. Market Drivers

22. Market Barriers

23. Appendix
23.1. Report Methodology

24. Researcher Capabilities

25. Disclaimer

26. About the Publisher

List of Tables
Table 1: Total Diagnosed Prevalent Population of Hot Flashes Associated with Prostate Cancer Treatment in the 7MM Countries (2017–2028)
Table 2: Diagnosed Prevalent Population of Prostate Cancer in the United States (2017–2028)
Table 3: Prostate Cancer by Stages in the United States (2017–2028)
Table 4: Progression from local and regional to advance stage in the United States (2017–2028)
Table 5: Hormone-sensitivity of Prostate Cancer in Advance Stage in the United States (2017–2028)
Table 6: ADT use in Prostate cancer in the United States (2017–2028)
Table 7: Rate of Hot Flashes Associated with Prostate Cancer Treatment in the United States (2017–2028)
Table 8: Hot Flashes by Severity in the United States (2017–2028)
Table 9: Diagnosed Prevalent Population of Prostate Cancer in Germany (2017–2028)
Table 10: Prostate Cancer by Stages in Germany (2017–2028)
Table 11: Progression from local and regional to advance stage in Germany (2017–2028)
Table 12: Hormone-sensitivity of Prostate Cancer in Advance Stage in Germany (2017–2028)
Table 13: ADT use in Prostate cancer in Germany (2017–2028)
Table 14: Rate of Hot Flashes Associated with Prostate Cancer Treatment in Germany (2017–2028)
Table 15: Hot Flashes by Severity in Germany (2017–2028)
Table 16: Diagnosed Prevalent Population of Prostate Cancer in France (2017–2028)
Table 17: Prostate Cancer by Stages in France (2017–2028)
Table 18: Progression from local and regional to advance stage in France (2017–2028)
Table 19: Hormone-sensitivity Prostate Cancer in Advance Stage in France (2017–2028)
Table 20: ADT use in Prostate cancer in France (2017–2028)
Table 21: Rate of Hot Flashes Associated with Prostate Cancer Treatment in France (2017–2028)
Table 22: Hot Flashes by Severity in France (2017–2028)
Table 23: Diagnosed Prevalent Population of Prostate Cancer in Italy (2017–2028)
Table 24: Prostate Cancer by Stages in Italy (2017–2028)
Table 25: Progression from local and regional to advance stage in Italy (2017–2028)
Table 26: Hormone-sensitivity of Prostate Cancer in Advance Stage in Italy (2017–2028)
Table 27: ADT use in Prostate cancer in Italy (2017–2028)
Table 28: Rate of Hot Flashes Associated with Prostate Cancer Treatment in Italy (2017–2028)
Table 29: Hot Flashes by Severity in Italy (2017–2028)
Table 30: Diagnosed Prevalent Population of Prostate Cancer in Spain (2017–2028)
Table 31: Prostate Cancer by Stages in Spain (2017–2028)
Table 32: Progression from local and regional to advance stage in Spain (2017–2028)
Table 33: Hormone-sensitivity of Prostate Cancer in Advance Stage in Spain (2017–2028)
Table 34: ADT use in Prostate cancer in Spain (2017–2028)
Table 35: Rate of Hot Flashes Associated with Prostate Cancer Treatment in Spain (2017–2028)
Table 36: Hot Flashes by Severity in Spain (2017–2028)
Table 37: Diagnosed Prevalent Population of Prostate Cancer in the United Kingdom (2017–2028)
Table 38: Prostate Cancer by Stages in the United Kingdom (2017–2028)
Table 39: Progression from local and regional to advance stage in the United Kingdom (2017–2028)
Table 40: Hormone-sensitivity of Prostate Cancer in Advance Stage in the United Kingdom (2017–2028)
Table 41: ADT use in Prostate cancer in the United Kingdom (2017–2028)
Table 42: Rate of Hot Flashes Associated with Prostate Cancer Treatment in the United Kingdom (2017–2028)
Table 43: Hot Flashes by Severity in the United Kingdom (2017–2028)
Table 44: Diagnosed Prevalent Population of Prostate Cancer in Japan (2017–2028)
Table 45: Prostate Cancer by Stages in Japan (2017–2028)
Table 46: Progression from local and regional to advance stage in Japan (2017–2028)
Table 47: Hormone-sensitivity of Prostate Cancer in Advance Stage in Japan (2017–2028)
Table 48: ADT use in Prostate cancer in Japan (2017–2028)
Table 49: Rate of Hot Flashes Associated with Prostate Cancer Treatment in Japan (2017–2028)
Table 50: Hot Flashes by Severity in Japan (2017–2028)
Table 51: Zuclomiphene citrate, Clinical Trial Description
Table 52: 7 Major Market Size of Hot Flashes Associated with Prostate Cancer Treatment in USD Million (2017–2028)
Table 53: United States Market Size of Hot Flashes Associated with Prostate Cancer Treatment, USD Million (2017–2028)
Table 54: Market size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in the United States, in USD Million (2017–2028)
Table 55: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in Germany, in USD Million (2017–2028)
Table 56: Market size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in Germany, in USD Million (2017–2028)
Table 57: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in France, in USD Million (2017–2028)
Table 58: Market size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in France, in USD Million (2017–2028)
Table 59: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in Italy, in USD Million (2017–2028)
Table 60: Market size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in Italy, in USD Million (2017–2028)
Table 61: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in Spain, in USD Million (2017–2028)
Table 62: Market size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in Spain, in USD Million (2017–2028)
Table 63: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in the UK, in USD Million (2017–2028)
Table 64: Market size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in the UK, in USD Million (2017–2028)
Table 65: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in Japan, in USD Million (2017–2028)
Table 66: Market size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in Japan, in USD Million (2017–2028)

List of Figures
Figure 1: Risk Factors of Prostate Cancer
Figure 2: Staging for Prostate Cancer
Figure 3: TNM Staging System for Prostate Cancer
Figure 4: Illustration of Proposed Pathophysiologic Contributors to the Experience of Hot Flashes
Figure 5: Preliminary Tests
Figure 6: Confirmatory Tests
Figure 7: Imaging Tests
Figure 8: Diagnostic Algorithm of Prostate Cancer
Figure 9: Total Diagnosed Prevalent Patient Population of Hot Flashes Associated with Prostate Cancer Treatment in the 7MM Countries (2017–2028)
Figure 10: Diagnosed Prevalent Population of Prostate Cancer in the United States (2017–2028)
Figure 11: Prostate Cancer by Stages in the United States (2017–2028)
Figure 12: Progression from local and regional to advance stage in the United States (2017–2028)
Figure 13: Hormone-sensitivity of Prostate Cancer in Advance Stage in the United States (2017–2028)
Figure 14: ADT use in Prostate cancer in the United States (2017–2028)
Figure 15: Rate of Hot Flashes Associated with Prostate Cancer Treatment in the United States (2017–2028)
Figure 16: Hot Flashes by Severity in the United States (2017–2028)
Figure 17: Diagnosed Prevalent Population of Prostate Cancer in Germany (2017–2028)
Figure 18: Prostate Cancer by Stages in Germany (2017–2028)
Figure 19: Progression from local and regional to advance stage in Germany (2017–2028)
Figure 20: Hormone-sensitivity of Prostate Cancer in Advance Stage in Germany (2017–2028)
Figure 21: ADT use in Prostate cancer in Germany (2017–2028)
Figure 22: Rate of Hot Flashes Associated with Prostate Cancer Treatment in Germany (2017–2028)
Figure 23: Hot Flashes by Severity in Germany (2017–2028)
Figure 24: Diagnosed Prevalent Population of Prostate Cancer in France (2017–2028)
Figure 25: Prostate Cancer by Stages in France (2017–2028)
Figure 26: Progression from local and regional to advance stage in France (2017–2028)
Figure 27: Hormone-sensitivity Prostate Cancer in Advance Stage in France (2017–2028)
Figure 28: ADT use in Prostate cancer in France (2017–2028)
Figure 29: Rate of Hot Flashes Associated with Prostate Cancer Treatment in France (2017–2028)
Figure 30: Hot Flashes by Severity in France (2017–2028)
Figure 31: Diagnosed Prevalent Population of Prostate Cancer in Italy (2017–2028)
Figure 32: Prostate Cancer by Stages in Italy (2017–2028)
Figure 33: Progression from local and regional to advance stage in Italy (2017–2028)
Figure 34: Hormone-sensitivity of Prostate Cancer in Advance Stage in Italy (2017–2028)
Figure 35: ADT use in Prostate cancer in Italy (2017–2028)
Figure 36: Rate of Hot Flashes Associated with Prostate Cancer Treatment in Italy (2017–2028)
Figure 37: Hot Flashes by Severity in Italy (2017–2028)
Figure 38: Diagnosed Prevalent Population of Prostate Cancer in Spain (2017–2028)
Figure 39: Prostate Cancer by Stages in Spain (2017–2028)
Figure 40: Progression from local and regional to advance stage in Spain (2017–2028)
Figure 41: Hormone-sensitivity of Prostate Cancer in Advance Stage in Spain (2017–2028)
Figure 42: ADT use in Prostate cancer in Spain (2017–2028)
Figure 43: Rate of Hot Flashes Associated with Prostate Cancer Treatment in Spain (2017–2028)
Figure 44: Hot Flashes by Severity in Spain (2017–2028)
Figure 45: Diagnosed Prevalent Population of Prostate Cancer in the United Kingdom (2017–2028)
Figure 46: Prostate Cancer by Stages in the United Kingdom (2017–2028)
Figure 47: Progression from local and regional to advance stage in the United Kingdom (2017–2028)
Figure 48: Hormone-sensitivity of Prostate Cancer in Advance Stage in the United Kingdom (2017–2028)
Figure 49: ADT use in Prostate cancer in the United Kingdom (2017–2028)
Figure 50: Rate of Hot Flashes Associated with Prostate Cancer Treatment in the United Kingdom (2017–2028)
Figure 51: Hot Flashes by Severity in the United Kingdom (2017–2028)
Figure 52: Diagnosed Prevalent Population of Prostate Cancer in Japan (2017–2028)
Figure 53: Prostate Cancer by Stages in Japan (2017–2028)
Figure 54: Progression from local and regional to advance stage in Japan (2017–2028)
Figure 55: Hormone-sensitivity of Prostate Cancer in Advance Stage in Japan (2017–2028)
Figure 56: ADT use in Prostate cancer in Japan (2017–2028)
Figure 57: Rate of Hot Flashes Associated with Prostate Cancer Treatment in Japan (2017–2028)
Figure 58: Hot Flashes by Severity in Japan (2017–2028)
Figure 59: Treatment for Hot Flashes in men
Figure 60: Unmet Needs
Figure 61: 7 Major Market Size of Hot Flashes Associated with Prostate Cancer Treatment in USD Million (2017–2028)
Figure 62: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in the United States, USD Millions (2017–2028)
Figure 63: Market size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in the US, in USD Million (2017–2028)
Figure 64: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in Germany, USD Million (2017–2028)
Figure 65: Market Size of Hot Flashes Associated with Prostate Cancer Treatment by therapies, in Germany, in USD Million (2017–2028)
Figure 66: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in France, USD Million (2017–2028)
Figure 67: Market Size of Hot Flashes Associated with Prostate Cancer Treatment by therapies, in France, in USD Million (2017–2028)
Figure 68: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in Italy, USD Million (2017–2028)
Figure 69: Market Size of Hot Flashes Associated with Prostate Cancer Treatment by therapies, in Italy, in USD Million (2017–2028)
Figure 70: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in Spain, USD Million (2017–2028)
Figure 71: Market Size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in Spain, in USD Million (2017–2028)
Figure 72: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in the UK, USD Million (2017–2028)
Figure 73: Market Size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in the UK, in USD Million (2017–2028)
Figure 74: Market Size of Hot Flashes Associated with Prostate Cancer Treatment in Japan, USD Million (2017–2028)
Figure 75: Market Size of Hot Flashes Associated with Prostate Cancer Treatment by therapies in Japan, in USD Million (2017–2028)
Figure 76: Market Drivers
Figure 77: Market Barriers

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Veru Pharma
Note: Product cover images may vary from those shown
Adroll
adroll